Phase i clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours

European Journal of Cancer

Volumn 51, Issue 2, 2015, Pages 146-156

  Weihrauch, Martin R ^a,e   Richly, Heike ^b   Von Bergwelt Baildon, Michael S ^a   Becker, Hans Jiro ^a   Schmidt, Manuel ^c   Hacker, Ulrich T ^a   Shimabukuro Vornhagen, Alexander ^a   Holtick, Udo ^a   Nokay, Bahar ^b   Schroff, Matthias ^c   Wittig, Burghardt ^d   Scheulen, Max E ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c MOLOGEN AG   (Germany)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Immunotherapy; MGN1703; TLR9

Indexed keywords

ANTINEOPLASTIC AGENT; MGN 1703; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; DNA; IMMUNOLOGIC FACTOR; MGN1703; TLR9 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 9;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERHIDROSIS; IMMUNOMODULATION; INJECTION SITE REACTION; MALAISE; MALE; METASTATIC SOLID TUMOR; MIDDLE AGED; MYALGIA; NAUSEA; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SOLID TUMOR; AGONISTS; B LYMPHOCYTE; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; LYMPHOCYTE COUNT; METABOLISM; METASTASIS; NEOPLASMS; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PARTIAL THROMBOPLASTIN TIME; TOLL-LIKE RECEPTOR 9; TREATMENT OUTCOME;

EID: 84925447071     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.11.002     Document Type: Article

References (31)

1. M. Schmidt, K. Anton, C. Nordhaus, C. Junghans, B. Wittig, and M. Worm Cytokine and Ig-production by CG-containing sequences with phosphorodiester backbone and dumbbell-shape Allergy 61 1 2006 56 63
2. H. Kanzler, F.J. Barrat, E.M. Hessel, and R.L. Coffman Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists Nat Med 13 5 2007 552 559
3. U. Holtick, M.E. Scheulen, M.S. von Bergwelt-Baildon, and M.R. Weihrauch Toll-like receptor 9 agonists as cancer therapeutics Exp Opin Invest Drugs 20 3 2011 361 372
4. P. Ahmad-Nejad, H. Häcker, M. Rutz, S. Bauer, R.M. Vabulas, and H. Wagner Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments Eur J Immunol 32 7 2002 1958 1968
5. A.M. Krieg Therapeutic potential of Toll-like receptor 9 activation Nat Rev Drug Discov 5 6 2006 471 484
6. A.M. Krieg CpG motifs in bacterial DNA and their immune effects Annu Rev Immunol 20 2002 709 760
7. Y.-J. Liu IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors Annu Rev Immunol 23 2005 275 306
8. J.S. Weber, H. Zarour, B. Redman, U. Trefzer, S. O'Day, and A.J.M. van den Eertwegh Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma Cancer 115 17 2009 3944 3954
9. M. Pashenkov, G. Goëss, C. Wagner, M. Hörmann, T. Jandl, and A. Moser Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma J Clin Oncol 24 36 2006 5716 5724
10. D.E. Speiser, D. Liénard, N. Rufer, V. Rubio-Godoy, D. Rimoldi, and F. Lejeune Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909 J Clin Invest 115 3 2005 739 746
11. B.G. Molenkamp, P.A.M. van Leeuwen, S. Meijer, B.J.R. Sluijter, P.G.J.T.B. Wijnands, and A. Baars Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients Clin Cancer Res 13 10 2007 2961 2969
12. A. Carpentier, F. Laigle-Donadey, S. Zohar, L. Capelle, A. Behin, and A. Tibi Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma Neuro-oncology 8 1 2006 60 66
13. J.W. Friedberg, H. Kim, M. McCauley, E.M. Hessel, P. Sims, and D.C. Fisher Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity Blood 105 2 2005 489 495
14. V. Hirsh, L. Paz-Ares, M. Boyer, R. Rosell, G. Middleton, and W. Eberhardt Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer J Clin Oncol 29 2011 2667 2674
15. C. Manegold, N. van Zandwijk, A. Szczesna, P. Zatloukal, J. Au, and M. Blasinska-Morawiec A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer Ann Oncol 23 2012 72 77
16. J.P. Sheehan, and H.C. Lan Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex Blood 92 5 1998 1617 1625
17. S.P. Henry, W. Novotny, J. Leeds, C. Auletta, and D.J. Kornbrust Inhibition of coagulation by a phosphorothioate oligonucleotide Antisense Nucl Acid Drug Dev 7 5 1997 503 510
18. T.L.H. Jason, J. Koropatnick, and R.W. Berg Toxicology of antisense therapeutics Toxicol Appl Pharmacol 201 1 2004 66 83
19. S.P. Henry, R.S. Geary, R. Yu, and A.A. Levin Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors? Curr Opin Invest Drugs 2 10 2001 1444 1449
20. M. Schmidt DSLIM immunomodulators reduce tumor growth in various animal tumor models Mol Ther 16 Suppl. 1 2008 389 [Abstract 935]
21. M. Schmidt Potent phosphorodiester-based DNA immunomodulators (dSLIM) exhibit enhanced safety compared to phosphorothioate-based oligonucleotides Blood 106 Suppl. 1 2005 59b [Abstract 3915]
22. M. Schmidt Immune-modulatory function of CpG sequence motifs in covalently-closed, double-stem-loop DNA constructs (dSLIM) Blood 102 Suppl. 1 2003 769a [Abstract 2840]
23. M. Schmidt DSLIM immunomodulators induce anti-tumor responses both in vitro and in vivo Blood 108 1 2006 490a [Abs 1727]
24. M.R. Weihrauch, S. Ansén, E. Jurkiewicz, C. Geisen, Z. Xia, and K.S. Anderson Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer Clin Cancer Res 11 16 2005 5993 6001
25. B. Wittig, A. Märten, T. Dorbic, S. Weineck, H. Min, and S. Niemitz Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial Hum Gene Ther 12 3 2001 267 278
26. A.P. Vicari, T. Schmalbach, J. Lekstrom-Himes, M.L. Morris, M.J. Al-Adhami, and C. Laframboise Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist Antivir Ther 12 5 2007 741 751
27. H.T. Ichikawa, L.P. Williams, and B.M. Segal Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease J Immunol 169 5 2002 2781 2787
28. A. Ronaghy, B.J. Prakken, K. Takabayashi, G.S. Firestein, D. Boyle, and N.J. Zvailfler Immunostimulatory DNA sequences influence the course of adjuvant arthritis J Immunol 168 1 2002 51 56
29. M.A. Hofmann, C. Kors, H. Audring, P. Walden, W. Sterry, and U. Trefzer Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma J Immunother 31 5 2008 520 527
30. B.K. Link, Z.K. Ballas, D. Weisdorf, J.E. Wooldridge, A.D. Bossler, and M. Shannon Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma J Immunother 29 5 2006 558 568
31. H.J. Schmoll, B. Wittig, D. Arnold, J. Riera-Knorrenschild, D. Nitsche, and H. Kroening Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial J Cancer Res Clin Oncol 2014 140 2014 1615 1624